Cargando…

Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia

PURPOSE: To assess the effects of Aleglitazar on hyperglycaemia-induced apoptosis. METHODS: We incubated human cardiomyocytes, cardiomyocytes from cardiac-specific peroxisome proliferator-activated receptor-γ knockout or wild-type mice in normoglycaemic or hyperglycaemic conditions (glucose 25 mM)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yan, Chen, Hongmei, Birnbaum, Yochai, Nanhwan, Manjyot K, Bajaj, Mandeep, Ye, Yumei, Qian, Jinqiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5305042/ https://www.ncbi.nlm.nih.gov/pubmed/28111985 http://dx.doi.org/10.1177/1479164116679081

Ejemplares similares

Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
por: Birnbaum, Yochai, et al.
Publicado: (2016)

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
por: Hansen, Barbara C, et al.
Publicado: (2011)

Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice
por: Boujon, Valérie, et al.
Publicado: (2019)

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study
por: Ruilope, Luis, et al.
Publicado: (2014)

Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
por: Dietz, Michel, et al.
Publicado: (2012)

Dipyridamole with Low-Dose Aspirin Augments the Infarct Size-Limiting Effects of Simvastatin
por: Ye, Yumei, et al.
Publicado: (2011)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer
por: Huang, Guodong, et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptor γ Activity is Required for Appropriate Cardiomyocyte Differentiation
por: Peymani, Maryam, et al.
Publicado: (2016)

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
por: Koomen, Jeroen V., et al.
Publicado: (2019)

Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar
por: Grobbee, Esmée J., et al.
Publicado: (2022)

Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis
por: Caglayan, Evren, et al.
Publicado: (2008)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

A novel specific peroxisome proliferator‐activated receptor γ (PPARγ) modulator YR4‐42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet‐induced obese mice
por: Huan, Yi, et al.
Publicado: (2019)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis
por: Suzuki, Shugo, et al.
Publicado: (2016)

Peroxisome proliferator-activated receptor γ agonist suppresses mast cell maturation and induces apoptosis
por: Zhang, Yu, et al.
Publicado: (2017)

Cardiac Peroxisome Proliferator-Activated Receptor-γ Expression is Modulated by Oxidative Stress in Acutely Infrasound-Exposed Cardiomyocytes
por: Pei, Zhaohui, et al.
Publicado: (2013)

Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure
por: Chen, Rui, et al.
Publicado: (2016)

Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial
por: Ormseth, Michelle J, et al.
Publicado: (2013)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Renal-Protective Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone in ob/ob Mice
por: Li, Ying, et al.
Publicado: (2019)

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
por: Hasni, Sarfaraz, et al.
Publicado: (2022)

HMGB1 mediates hyperglycaemia-induced cardiomyocyte apoptosis via ERK/Ets-1 signalling pathway
por: Wang, Wen-Ke, et al.
Publicado: (2014)

Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress
por: Sekulic-Jablanovic, Marijana, et al.
Publicado: (2017)

Hyperglycaemia and risk of adverse perinatal outcomes: systematic review and meta-analysis
por: Farrar, Diane, et al.
Publicado: (2016)

Rapid Diagnosis of STEMI Equivalent in Patients With Left Bundle‐Branch Block: Is It Feasible?
por: Birnbaum, Yochai, et al.
Publicado: (2021)

Benzoxazinones as Human Peroxisome Proliferator Activated Receptor Gamma (PPARγ) Agonists: A Docking Study Using Glide
por: Das, N., et al.
Publicado: (2011)

MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism
por: Kim, Seok-Ho, et al.
Publicado: (2019)

The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase
por: Zhang, Dapeng, et al.
Publicado: (2020)

Risk Factors for Doxorubicin-Induced Serious Hyperglycaemia-Related Adverse Drug Reactions
por: Yang, Jincheng, et al.
Publicado: (2019)

The Role of Peroxisome Proliferator-Activated Receptor and Effects of Its Agonist, Pioglitazone, on a Rat Model of Optic Nerve Crush: PPARγ in Retinal Neuroprotection
por: Zhu, Juming, et al.
Publicado: (2013)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

Involvement of the Retinoid X Receptor Ligand in the Anti-Inflammatory Effect Induced by Peroxisome Proliferator-Activated Receptor γ Agonist In Vivo
por: Yamamoto, Atsuki, et al.
Publicado: (2011)

CMHX008, a Novel Peroxisome Proliferator-Activated Receptor γ Partial Agonist, Enhances Insulin Sensitivity In Vitro and In Vivo
por: Ming, Yue, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_l6f3l85856d9638am58vjgu7hc